Osteonecrosis of the jaw: a rare and devastating side effect of bisphosphonates

被引：11
作者：
Ryan, P. [1 ]
Saleh, I. [1 ]
Stassen, L. F. A. [1 ]
机构：
[1] St James Hosp, Dept Oral & Maxillofacial Surg, Dublin 8, Ireland
来源：
POSTGRADUATE MEDICAL JOURNAL | 2009年 / 85卷 / 1010期
关键词：
RISK-FACTORS; AVASCULAR NECROSIS; ZOLEDRONIC ACID; CANCER; BONE;
D O I：
10.1136/pgmj.2008.076349
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Evidence has emerged that bisphosphonate use in cancer patients is associated with osteonecrosis of the jaw. This form of osteonecrosis has been termed bisphosphonate induced osteonecrosis of the jaw (BIONJ). BIONJ is commonly precipitated by a tooth extraction in patients treated with long term, potent, high dose intravenous bisphosphonates for the management of myeloma, breast or prostate cancer. The overall prevalence of BIONJ is about 5% in patients with these malignancies. Current evidence shows that the risk of BIONJ in non-cancerous patients, such as those with osteoporosis, is very low and appears to be comparable with that of the general population. Prescribing physicians need to encourage cancer patients to see their dentists before the initiation of bisphosphonate treatment, and regularly thereafter.
引用
收藏
页码：674 / 677
页数：4
相关论文
共 27 条
  • [1] Guidance on the use of bisphosphonates in solid tumours:: recommendations of an international expert panel
    Aapro, M.
    Abrahamsson, P. A.
    Body, J. J.
    Coleman, R. E.
    Colomer, R.
    Costa, L.
    Crino, L.
    Dirix, L.
    Gnant, M.
    Gralow, J.
    Hadji, P.
    Hortobagyi, G. N.
    Jonat, W.
    Lipton, A.
    Monnier, A.
    Paterson, A. H. G.
    Rizzoli, R.
    Saad, F.
    Thuerlimann, B.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 (03) : 420 - 432
  • [2] Bis-phossy jaws - High and low risk factors for bisphosphonate-induced osteonecrosis of the jaw
    Abu-Id, Mario H.
    Warnke, Patrick H.
    Gottschalk, Joachim
    Springer, Ingo
    Wiltfang, Joerg
    Acil, Yahya
    Russ, Paul A. J.
    Kreusch, Thomas
    [J]. JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY, 2008, 36 (02) : 95 - 103
  • [3] American Academy of Oral and Maxillofacial Surgeons, POS PAP BISPH REL OS
  • [4] Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors
    Badros, A
    Weikel, D
    Salama, A
    Goloubeva, O
    Schneider, A
    Rapoport, A
    Fenton, R
    Gahres, N
    Sausville, E
    Ord, R
    Meiller, T
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (06) : 945 - 952
  • [5] Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors
    Bamias, A
    Kastritis, E
    Bamia, C
    Moulopoulos, LA
    Melakopoulos, L
    Bozas, G
    Koutsoukou, V
    Gika, D
    Anagnostopoulos, A
    Papadimitriou, C
    Terpos, E
    Dimopoulos, MA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) : 8580 - 8587
  • [6] A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma
    Corso, A.
    Varettoni, M.
    Zappasodi, P.
    Klersy, C.
    Mangiacavalli, S.
    Pica, G.
    Lazzarino, M.
    [J]. LEUKEMIA, 2007, 21 (07) : 1545 - 1548
  • [7] Esophagitis associated with the use of alendronate
    deGroen, PC
    Lubbe, DF
    Hirsch, LJ
    Daifotis, A
    Stephenson, W
    Freedholm, D
    PryorTillotson, S
    Seleznick, MJ
    Pinkas, H
    Wang, KK
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (14) : 1016 - 1021
  • [8] Dixon RB, 1997, J DENT RES, V76, P2579
  • [9] Durie BGM, 2005, NEW ENGL J MED, V353, P99
  • [10] GROTZ KA, 2006, DZZ, V60, P10
123